Stage Ib Trial of mSMART With Varenicline

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2018

Primary Completion Date

January 31, 2019

Study Completion Date

June 30, 2019

Conditions
Nicotine Dependence
Interventions
DEVICE

mSMART

A smartphone application that targets medication adherence in substance users, providing information and reminders and tracking medication usage and factors interfering with adherence.

DRUG

Chantix

For the first 3 days smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12-week active treatment duration.

Trial Locations (1)

27705

Duke Health Behavior Neuroscience Research Lab, Durham

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Intelligent Automation, Inc.

INDUSTRY

collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Duke University

OTHER

NCT03069768 - Stage Ib Trial of mSMART With Varenicline | Biotech Hunter | Biotech Hunter